Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 11, 2016Clinical Chemistry and Laboratory Medicine (CCLM)

miRNAs as novel biomarkers in the management of prostate cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

XFXavier FilellaHospital Clínic de BarcelonaLFLaura FojHospital Universitari Arnau de Vilanova

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Filella et al. (2016) studied this question.

synapsesocial.com/papers/6aa95ae7a35b18e46c050246https://doi.org/10.1515/cclm-2015-1073
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM2012 · 219 citations
  2. 2Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer2014 · 101 citations
  3. 3Combinations of Serum Prostate-Specific Antigen and Plasma Expression Levels of let-7c, miR-30c, miR-141, and miR-375 as Potential Better Diagnostic Biomarkers for Prostate Cancer2014 · 111 citations
  4. 4Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies2011 · 886 citations